1
March 2024
Oncimmune Holdings
plc
("Oncimmune" or the "Company")
Investor
Presentation via Investor Meet Company
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company to the pharmaceutical and
biotechnology industry, is pleased to announce that Martin
Gouldstone, CEO, and Martin Hudson, CFO, will provide a live
presentation relating to the FY2023 results, which were announced
on 29 February, via Investor Meet Company on 07 Mar 2024, 10:30
GMT.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 06 Mar
2024, 09:00 GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Oncimmune via:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Investors who already follow
Oncimmune on the Investor Meet Company platform will automatically
be invited.
For further
information:
Oncimmune
Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated
Adviser and Broker)
Philip Davies, Harry Gooden, James
Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the
UK, with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com